Abcam, ab265215, Human SLPI knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
SLPI KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 1,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SLPI, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Secretory leukocyte protease inhibitor (SLPI) also known as antileukoproteinase and neutrophil elastase inhibitor is a protein with a molecular mass of approximately 12 kDa. SLPI is found mainly in epithelial tissues and is expressed in locations such as the respiratory tract skin and cervix. Mechanically SLPI functions as a serine protease inhibitor binding to and neutralizing enzymes like neutrophil elastase cathepsin G and trypsin which helps to limit tissue damage during inflammation.
Biological function summary
SLPI serves as a protector of epithelial surfaces from proteolytic degradation and acts as an anti-inflammatory agent. It displays broad-spectrum antimicrobial properties providing protection against bacterial and viral infections. Although SLPI is not part of a complex itself its interactions with extracellular matrix proteins help modulate wound healing processes and maintain tissue integrity.
Pathways
SLPI participates in the innate immune response and inflammation regulation pathways. It interacts within pathways that involve the complement cascade and kallikrein-kinin system helping to regulate inflammation and modulate immune responses. During these processes SLPI is related to proteins such as alpha-1-antitrypsin in its role as a protease inhibitor contributing to the regulation of protease activity and inflammatory responses.
SLPI is implicated in conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis where excessive protease activity leads to tissue damage. In these diseases SLPI shows a protective role against lung tissue degradation. SLPI is also associated with the progression of certain cancers like ovarian cancer where its overexpression may support tumor growth and metastasis. In these contexts SLPI relates to other protease inhibitors such as tissue inhibitors of metalloproteinases (TIMPs) due to their shared function in regulating protease activity and tissue remodeling.